title: Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
abstract: BACKGROUND
  Microsatelite instability (MSI) is the consequence of the inactivation of a mismatch repair gene and is observed in approximately 15% of colon cancer cases. Patients with MSI colon cancer do not benefit from 5-fluorouracil (5-FU)-based chemotherapy. A current treatment of reference for colon cancer is a combination of 5-FU and oxaliplatin (FOLFOX). The aim of this study was to determine the efficiency of the FOLFOX treatment in patients with metastatic MSI colon cancer.
  
  
  METHODS
  Tumour specimens were collected from patients with metastatic colon cancer treated with FOLFOX 4 modified or FOLFOX 6; these two regimens are based on 85 mg/m2 and 100 mg/m2 oxaliplatin, respectively. The MSI status was assessed by measuring the length of five monomorphic mononucleotide markers. The FOLFOX regimen was evaluated as a first-line treatment according to WHO criteria.
  
  
  RESULTS
  Forty patients (22 men, 18 women), median age 63.5 years (27-83 years) were treated with FOLFOX 4 or 6. Nine patients had tumours exhibiting high MSI (MSI group) and 31 patients had tumours exhibiting microsatellite stability (MSS group). In the MSS group, 11 partial responses (36%) were observed, while there were only two in the MSI group (22%) (no significant difference). The two patients who were responders in the MSI group were treated with FOLFOX 6. The overall survival was not significantly different for MSI and MSS patients.
  
  
  CONCLUSIONS
  No significant differences in the overall response rate or overall survival between the two groups of patients were observed. However, these results suggest that patients with MSI colon cancer are more sensitive to a higher dose of FOLFOX.
authors: Department of Oncology, Avicenne Hospital, 93009 Bobigny, France. Gaetan.des-guetz@wanadoo.fr
authors: G
authors: G
authors: des Guetz
authors: P
authors: P
authors: Mariani
authors: J
authors: J
authors: Cucherousset
authors: M
authors: M
authors: Benamoun
authors: C
authors: C
authors: Lagorce
authors: X
authors: X
authors: Sastre
authors: P
authors: P
authors: Le Toumelin
authors: B
authors: B
authors: Uzzan
authors: G Y
authors: GY
authors: Perret
authors: J F
authors: JF
authors: Morere
authors: J L
authors: JL
authors: Breau
authors: R
authors: R
authors: Fagard
authors: P O
authors: PO
authors: Schischmanoff
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil